Health Care/Hospital

Lynk Pharmaceuticals Reports Positive Long-Term Phase III Results for Zemprocitinib in bDMARDs-Inadequate Responders with Moderate-to-Severe Rheumatoid Arthritis

HANGZHOU, China, SHANGHAI and BOSTON, Oct. 28, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced positive long-term results from its pivotal Phase III clin...

2026-10-28 08:00

Fosun Health Makes Historic Debut at Canton Fair, Foshan Fosun Chancheng Hospital Showcases International Healthcare Services

GUANGZHOU, China, Oct. 28, 2026 /PRNewswire/ -- Fosun Health has become the first cross-border international healthcare group to exhibit at the Canton Fair in its 70-year history, debuting at the event's inaugural International Healthcare Zone alongside four Greater Bay Area (GBA) hospitals, incl...

2026-10-28 08:00

How to Care for Caregivers? NCCN Debuts Essential Guide for Supporting Loved Ones with Cancer

New, free book offers simple but empowering information on how to care for people with cancer while also caring for yourself. PLYMOUTH MEETING, Pa., Oct. 27, 2026 /PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers in the United States ...

2026-10-27 20:07 1381

CityUHK survey: rising willingness to use AI in Hong Kong, but over half remain concerned about job displacement; Doctor-led medical decisions remain preferred

HONG KONG, Oct. 27, 2026 /PRNewswire/ -- A comprehensive survey on the societal impact of artificial intelligence (AI) recently released by City University of Hong Kong (CityUHK) examines public acceptance and trust in AI in two key areas: workplace employment and healthcare. The survey found tha...

2026-10-27 17:54 2322

HUAWEI WATCH D3 Debuts at ISH-ECS 2026, Bringing Advanced Blood Pressure Monitoring into Everyday Life

DUBAI, UAE, Oct. 27, 2026 /PRNewswire/ -- The 31st International Society of Hypertension Scientific Meeting and 17th Emirates Cardiac Society Annual Conference (ISH-ECS 2026) took place in Dubai from 22 to 25 October 2026. As a major international gathering dedicated to hypertension, the conferen...

2026-10-27 12:37 2812

Natus Celebrates Grand Opening of Suzhou Facility - Advancing Innovation in China, for China

Local development and manufacturing bring Natus neurodiagnostic expertise closer to clinicians and patients across China SUZHOU, China, Oct. 27, 2026 /PRNewswire/ -- Natus Medical Incorporated, the world's largest pure-play neurodiagnostic company, today celebrated the grand opening of its devel...

2026-10-27 11:13 2063

Asia-Pacific's First Whole-Body Clinical 5T MRI System Installed in Vietnam, Advancing a New Regional High-Field MRI Center of Excellence

HANOI, Vietnam, Oct. 27, 2026 /PRNewswire/ -- On October 26, 2026, United Imaging Healthcare's uMR Jupiter 5T MRI system was officially introduced at Hanoi Medical University Hospital (HMUH), marking the arrival ofthe first whole-body clinical 5T MRI in the Asia-Pacificregion (outside China). The...

2026-10-27 10:20 3645

Allianz Partners New Zealand brings Sonder's 24/7 health, safety and wellbeing support to international students

AUCKLAND, New Zealand, Oct. 27, 2026 /PRNewswire/ -- Allianz Partners New Zealand today announced a new service partnership with health, safety and wellbeing platform Sonder, providing international students with round-the-clock safety, medical and mental health support. Starting October 2026, S...

2026-10-27 04:30 2892

Final OS Analysis Results of Phase III OptiTROP-Breast01 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in Annals of Oncology

CHENGDU, China, Oct. 26, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, the results of the final overall survival (OS) analysis o...

2026-10-26 18:33 2854

Tencent Cloud Enhances Telehealth Experiences for Care, Safeguarding Every Doctor-Patient Connection

HONG KONG, Oct. 26, 2026 /PRNewswire/ -- Tencent Cloud, the cloud business of global technology company Tencent, today announced its collaboration with Care, one of Singapore's leading and most trusted telehealth digital solutions providers, to strengthen the quality and reliability of virtual he...

2026-10-26 16:57 1365

CStone Announces Major Clinical Validation Milestone for CS2009 at ESMO 2026: Data from More Than 300 Patients Support Mechanism, Safety and Broad Antitumor Activity

CS2009, an Innovative PD-1/VEGF/CTLA-4 trispecific antibody, demonstrates a differentiated profile through synergistic triple-pathway targeting, favorable tolerability and encouraging efficacy across multiple solid tumors Highlights * Three pillars of clinical validation: Clinical data from ov...

2026-10-26 16:45 1713

A Major Breakthrough in Smart Insurance Education: HK Insurance Hub Leverages AI Content Optimization to Demystify Protection for Hong Kong Citizens

HONG KONG, Oct. 26, 2026 /PRNewswire/ -- With the vast array of insurance products available and their often lengthy, complex terms, many citizens feel overwhelmed when choosing coverage. To advance public insurance education in Hong Kong, local insurance information hubHK Insurance Hub

2026-10-26 10:00 3458

Ascletis Announces FDA IND Submission of ASC39, an Oral Small Molecule Selective Amylin Receptor Agonist for the Treatment of Obesity

- ASC39, an oral small molecule selective amylin receptor agonist, demonstrated eloralintide-like amylin selectivity and efficacy in preclinical models. - ASC39 demonstrated eloralintide-like selectivity for human amylin 1 receptor (hAMY1R) over human calcitonin receptor (hCTR) (40-fold), support...

2026-10-26 08:10 5804

Antengene Presents Latest Clinical Results for ATG-022 and ATG-037 at ESMO 2026

SHANGHAI and HONG KONG, Oct. 26, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dis...

2026-10-26 08:00 2059

Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO

* Median OS was extended by 8.5 months compared with platinum-based doublet chemotherapy (25.9 vs 17.4 months), with a 31% reduction in the risk of death (HR 0.69; 95% CI 0.54–0.89; one-sided P = 0.0021). * The 2-year OS rate was 54.1% vs 37.2%, an improvement of 16.9%; with a median follow-u...

2026-10-25 19:12 4358

The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine

* PFS was significantly prolonged: as assessed by BICR, the risk of disease progression or death was reduced by 51% (HR 0.49; 95% CI 0.36-0.65; P<0.0001 ), and median PFS was 15.0 months (95% CI 9.9-NE) and 5.7 months (95% CI 5.5-7.4) in the two groups, respectively. * Responses were more dur...

2026-10-25 18:44 4979

Likang Life Sciences Showcases Personalized Cancer Immunotherapy and Global Ambitions at Abu Dhabi Future Health Summit 2026

BEIJING, Oct. 24, 2026 /PRNewswire/ -- Likang Life Sciences ("Likang"), a biotechnology company advancing AI-enabled personalized cancer immunotherapies, sponsored and exhibited at the Abu Dhabi Future Health Summit 2026, held from 20 to 22 October at ADNEC Centre Abu Dhabi. The summit marked a m...

2026-10-24 19:38 6948

Phase II Results of Sacituzumab Tirumotecan (sac-TMT) plus Pembrolizumab in Advanced Urothelial Carcinoma Presented at 2026 ESMO

CHENGDU, China, Oct. 24, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that at the 2026 European Society for Medical Oncology (ESMO) Congress held in Madrid, updated results from the Phase II MK-2870-002/SKB264-II-06 ...

2026-10-24 18:15 7491

19th EU-China Business Meeting Concludes! Third-Generation Triple-Helix Biomimetic Collagen Medical Devices Make Their Global Debut, Highlights from the Event

CHENGDU, China, Oct. 24, 2026 /PRNewswire/ -- At the 19th EU-China Business Meeting, co-hosted by the China Chamber of International Commerce (CCOIC) and the European Union Chamber of Commerce in China (EUCCC) in Chengdu, LivingPHOENIX Regenerative Technology Development (Chengdu) Co., Ltd. (her...

2026-10-24 09:29 7815

Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer

-  At the recommended Phase 3 dose (RP3D) of 1.6 mg/kg, zoci plus atezolizumab achieved a confirmed objective response rate of 81.8% (27/33) and an estimated 6-month progression-free survival rate of 81.9% (n=33) in 1L ES-SCLC -  Among patients with at least six-months follow-up (n=15) treated at...

2026-10-23 20:04 2783
12345 ... 523